Kamada (KMDA) Given Buy Rating at HC Wainwright
A number of other analysts also recently weighed in on the company. Jefferies Group restated a buy rating and issued a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Zacks Investment Research upgraded Kamada from a sell rating to a hold rating in a report on Wednesday, October 25th. ValuEngine upgraded Kamada from a sell rating to a hold rating in a report on Friday, January 5th. Finally, Chardan Capital started coverage on Kamada in a report on Friday, February 2nd. They issued a buy rating and a $7.00 price objective for the company. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $7.00.
Shares of Kamada (KMDA) opened at $5.00 on Thursday. The firm has a market capitalization of $201.32, a price-to-earnings ratio of 29.41 and a beta of 1.14. Kamada has a 1-year low of $3.75 and a 1-year high of $8.61. The company has a quick ratio of 2.73, a current ratio of 3.30 and a debt-to-equity ratio of 0.02.
A number of institutional investors have recently modified their holdings of KMDA. Jane Street Group LLC acquired a new stake in Kamada during the 3rd quarter worth about $112,000. Worth Venture Partners LLC acquired a new stake in Kamada during the 3rd quarter worth about $246,000. Navellier & Associates Inc acquired a new stake in Kamada during the 2nd quarter worth about $303,000. Analyst IMS Investment Management Services Ltd. grew its holdings in Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares during the period. Hedge funds and other institutional investors own 6.26% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Kamada (KMDA) Given Buy Rating at HC Wainwright” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/11/kamada-kmda-given-buy-rating-at-hc-wainwright.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.